Takeda is launching a sweeping multi-year restructuring expected to generate $1.25 billion in annualized gross savings by 2028. The Japanese pharmaceutical giant will use AI to automate manual tasks and flatten its management structure to speed decision-making and engagement with healthcare professionals.
The plan carries a steep upfront cost: approximately $940 million in restructuring expenses in fiscal year 2026, with additional outlays through 2028. However, Takeda confirms the move won’t impact its 2025 financial forecast.
Savings will be strategically redirected into late-stage R&D and upcoming product launches, focusing on core therapeutic areas-oncology, neuroscience, and rare diseases.
Incoming CEO Julie Kim, who takes over after a 12-year leadership tenure, called the overhaul essential to maintaining competitiveness and delivering on Takeda’s pipeline promise.
"Today, Takeda is setting the stage to make a greater impact on the lives of patients as we prepare to launch multiple new medicines," Kim said. "These steps will strengthen our ability to execute with speed while positioning ourselves for long-term growth."
The industry now watches whether this leaner, tech-driven model can convert massive restructuring costs into successful global drug launches.